Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $6.62 billion. The enterprise value is $6.40 billion.
| Market Cap | 6.62B |
| Enterprise Value | 6.40B |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 26.76 million shares outstanding. The number of shares has decreased by -3.69% in one year.
| Current Share Class | 21.70M |
| Shares Outstanding | 26.76M |
| Shares Change (YoY) | -3.69% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 6.55% |
| Owned by Institutions (%) | 74.49% |
| Float | 20.90M |
Valuation Ratios
The trailing PE ratio is 39.66 and the forward PE ratio is 25.48.
| PE Ratio | 39.66 |
| Forward PE | 25.48 |
| PS Ratio | 2.54 |
| Forward PS | 2.51 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | 18.45 |
| P/OCF Ratio | 12.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.40, with an EV/FCF ratio of 17.93.
| EV / Earnings | 37.94 |
| EV / Sales | 2.47 |
| EV / EBITDA | 14.40 |
| EV / EBIT | 23.15 |
| EV / FCF | 17.93 |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.21 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 3.86 |
| Interest Coverage | 5.61 |
Financial Efficiency
Return on equity (ROE) is 2.50% and return on invested capital (ROIC) is 3.01%.
| Return on Equity (ROE) | 2.50% |
| Return on Assets (ROA) | 1.79% |
| Return on Invested Capital (ROIC) | 3.01% |
| Return on Capital Employed (ROCE) | 3.12% |
| Weighted Average Cost of Capital (WACC) | 8.81% |
| Revenue Per Employee | $347,638 |
| Profits Per Employee | $22,658 |
| Employee Count | 7,450 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, BIO has paid $53.50 million in taxes.
| Income Tax | 53.50M |
| Effective Tax Rate | 24.07% |
Stock Price Statistics
The stock price has increased by +4.41% in the last 52 weeks. The beta is 1.06, so BIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +4.41% |
| 50-Day Moving Average | 272.38 |
| 200-Day Moving Average | 292.26 |
| Relative Strength Index (RSI) | 34.91 |
| Average Volume (20 Days) | 391,668 |
Short Selling Information
The latest short interest is 29, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 29 |
| Short Previous Month | 34 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BIO had revenue of $2.59 billion and earned $168.80 million in profits. Earnings per share was $6.24.
| Revenue | 2.59B |
| Gross Profit | 1.35B |
| Operating Income | 276.60M |
| Pretax Income | 222.30M |
| Net Income | 168.80M |
| EBITDA | 444.80M |
| EBIT | 276.60M |
| Earnings Per Share (EPS) | $6.24 |
Balance Sheet
The company has $1.56 billion in cash and $1.38 billion in debt, with a net cash position of $186.50 million or $6.97 per share.
| Cash & Cash Equivalents | 1.56B |
| Total Debt | 1.38B |
| Net Cash | 186.50M |
| Net Cash Per Share | $6.97 |
| Equity (Book Value) | 6.85B |
| Book Value Per Share | 255.37 |
| Working Capital | 2.03B |
Cash Flow
In the last 12 months, operating cash flow was $510.40 million and capital expenditures -$153.20 million, giving a free cash flow of $357.20 million.
| Operating Cash Flow | 510.40M |
| Capital Expenditures | -153.20M |
| Depreciation & Amortization | 168.20M |
| Net Borrowing | -500,000 |
| Free Cash Flow | 357.20M |
| FCF Per Share | $13.35 |
Margins
Gross margin is 52.01%, with operating and profit margins of 10.68% and 6.52%.
| Gross Margin | 52.01% |
| Operating Margin | 10.68% |
| Pretax Margin | 8.58% |
| Profit Margin | 6.52% |
| EBITDA Margin | 17.17% |
| EBIT Margin | 10.68% |
| FCF Margin | 13.79% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.69% |
| Shareholder Yield | 3.69% |
| Earnings Yield | 2.56% |
| FCF Yield | 5.42% |
Analyst Forecast
The average price target for BIO is $329.75, which is 33.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $329.75 |
| Price Target Difference | 33.22% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 2.68% |
| EPS Growth Forecast (5Y) | -18.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 3.23 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.23 |
| Piotroski F-Score | 6 |